For the year ending 2025-12-31, CRNX made $7,696K in revenue. -$464,415K in net income. Net profit margin of -6034.50%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue, net | 7,696 | 1,039 | ||
| General and administrative | - | 99,737 | ||
| Cost of product revenue | 1,076 | - | ||
| Research and development | 332,058 | 240,156 | ||
| Selling, general and administrative | 191,331 | - | ||
| Total operating expenses | 524,465 | 339,893 | ||
| Loss from operations | -516,769 | -338,854 | ||
| Other income (expense), net | - | -519 | ||
| Interest income | 51,989 | 41,435 | ||
| Other expense, net | -357 | - | ||
| Total other income, net | 51,632 | 40,916 | ||
| Loss before income taxes | -465,137 | - | ||
| Income tax expense | 180 | - | ||
| Loss before equity method investment | -465,317 | 297,938 | ||
| Loss on equity method investment | 0 | -470 | ||
| Net loss | -465,317 | -298,408 | ||
| Unrealized gain (loss) on investment securities | 1,074 | -14 | ||
| Unrealized loss on foreign currency | -172 | - | ||
| Total other comprehensive income (loss) | 902 | - | ||
| Comprehensive loss | -464,415 | -298,422 | ||
| Basic EPS | -4.95 | -3.69 | ||
| Diluted EPS | -4.95 | -3.69 | ||
| Basic Average Shares | 94,057,000 | 80,783,000 | ||
| Diluted Average Shares | 94,057,000 | 80,783,000 | ||
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)